Congenital disorder of glycosylation Ia: New differentially expressed proteins identified by 2-DE

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 267-271

  Richard, Eva ^a   Vega, Ana I ^a   Pérez, Belén ^a   Roche, Carmen ^b   Velázquez, Ramón ^b   Ugarte, Magdalena ^a   Pérez Cerdá, Celia ^a  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b HOSPITAL INFANTIL LA PAZ   (Spain)

Author keywords

Congenital disorders of glycosylation; Glycoproteome; Mutation; Phenotype; Two dimensional gel electrophoresis

Indexed keywords

AFAMIN; ALPHA 2 MACROGLOBULIN; ASPARTIC ACID; FIBRIN; FIBRINOGEN; HAPTOGLOBIN; METHIONINE; PROTEOME; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 1A; CONTROLLED STUDY; GLYCOSYLATION; HEMIZYGOTE; HUMAN; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS;

ALPHA 1-ANTITRYPSIN; ALPHA-MACROGLOBULINS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; FIBRIN; FIBRINOGEN; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; ISOELECTRIC FOCUSING; METABOLISM, INBORN ERRORS; PROTEIN BIOSYNTHESIS; PROTEINS; PROTEOME; PROTEOMICS; SERUM; SERUM ALBUMIN; TRANSFERRIN;

EID: 58249104091     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.036     Document Type: Article

References (36)

1. Ohtsubo K., and Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 126 (2006) 855-867
2. Jaeken J., and Matthijs G. Congenital disorders of glycosylation: a rapidly expanding disease family. Annu. Rev. Genomics Hum. Genet. 8 (2007) 261-278
3. Jaeken J., Hennet T., Freeze H.H., and Matthijs G. On the nomenclature of congenital disorders of glycosylation (CDG). J. Inherit. Metab. Dis. (2008)
4. Freeze H.H., and Aebi M. Altered glycan structures: the molecular basis of congenital disorders of glycosylation. Curr. Opin. Struct. Biol. 15 (2005) 490-498
5. Matthijs G., Schollen E., Pardon E., Veiga-Da-Cunha M., Jaeken J., Cassiman J.J., and Van Schaftingen E. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). Nat. Genet. 16 (1997) 88-92
6. Mills K., Mills P., Jackson M., Worthington V., Beesley C., Mann A., Clayton P., Grunewald S., Keir G., Young L., Langridge J., Mian N., and Winchester B. Diagnosis of congenital disorders of glycosylation type-I using protein chip technology. Proteomics 6 (2006) 2295-2304
7. Vodopiutz J., and Bodamer O.A. Congenital disorders of glycosylation - a challenging group of IEMs. J. Inherit. Metab. Dis. 31 (2008) 267-269
8. Harrison H.H., Miller K.L., Harbison M.D., and Slonim A.E. Multiple serum protein abnormalities in carbohydrate-deficient glycoprotein syndrome: pathognomonic finding of two-dimensional electrophoresis?. Clin. Chem. 38 (1992) 1390-1392
9. Mills K., Mills P.B., Clayton P.T., Johnson A.W., Whitehouse D.B., and Winchester B.G. Identification of alpha(1)-antitrypsin variants in plasma with the use of proteomic technology. Clin. Chem. 47 (2001) 2012-2022
10. Mills K., Mills P.B., Clayton P.T., Mian N., Johnson A.W., and Winchester B.G. The underglycosylation of plasma alpha 1-antitrypsin in congenital disorders of glycosylation type I is not random. Glycobiology 13 (2003) 73-85
11. Butler M., Quelhas D., Critchley A.J., Carchon H., Hebestreit H.F., Hibbert R.G., Vilarinho L., Teles E., Matthijs G., Schollen E., Argibay P., Harvey D.J., Dwek R.A., Jaeken J., and Rudd P.M. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology 13 (2003) 601-622
12. Henry H., Tissot J.D., Messerli B., Markert M., Muntau A., Skladal D., Sperl W., Jaeken J., Weidinger S., Heyne K., and Bachmann C. Microheterogeneity of serum glycoproteins and their liver precursors in patients with carbohydrate-deficient glycoprotein syndrome type I: apparent deficiencies in clusterin and serum amyloid P. J. Lab. Clin. Med. 129 (1997) 412-421
13. Kleinert P., Kuster T., Arnold D., Jaeken J., Heizmann C.W., and Troxler H. Effect of glycosylation on the protein pattern in 2-D-gel electrophoresis. Proteomics 7 (2007) 15-22
14. Pérez-Cerdá C., Quelhas D., Vega A.I., Ecay J., Vilarinho L., and Ugarte M. Screening using serum percentage of carbohydrate-deficient transferrin for congenital disorders of glycosylation in children with suspected metabolic disease. Clin. Chem. 54 (2008) 93-100
15. Van Schaftingen E., and Jaeken J. Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS Lett. 377 (1995) 318-320
16. A.I. Vega, C. Pérez-Cerdá, L.R. Desviat, G. Matthijs, M. Ugarte, B. Pérez, Functional analysis of three splicing mutations identified in the PMM2 gene: towards a new therapy for Congenital Disorder of Glycosylation type Ia, Hum. Mutat., in press.
17. Richard E., Monteoliva L., Juarez S., Perez B., Desviat L.R., Ugarte M., and Albar J.P. Quantitative analysis of mitochondrial protein expression in methylmalonic acidemia by two-dimensional difference gel electrophoresis. J. Proteome Res. 5 (2006) 1602-1610
18. Grunewald S., Schollen E., Van Schaftingen E., Jaeken J., and Matthijs G. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am. J. Hum. Genet. 68 (2001) 347-354
19. Maquat L.E. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat. Rev. Mol. Cell Biol. 5 (2004) 89-99
20. Mills P., Mills K., Clayton P., Johnson A., Whitehouse D., and Winchester B. Congenital disorders of glycosylation type I leads to altered processing of N-linked glycans, as well as underglycosylation. Biochem. J. 359 (2001) 249-254
21. Lehmensiek V., Sussmuth S.D., Brettschneider J., Tauscher G., Felk S., Gillardon F., and Tumani H. Proteome analysis of cerebrospinal fluid in Guillain-Barre syndrome (GBS). J. Neuroimmunol. 185 (2007) 190-194
22. Quero C., Colome N., Prieto M.R., Carrascal M., Posada M., Gelpi E., and Abian J. Determination of protein markers in human serum: analysis of protein expression in toxic oil syndrome studies. Proteomics 4 (2004) 303-315
23. Dowling P., O'Driscoll L., Meleady P., Henry M., Roy S., Ballot J., Moriarty M., Crown J., and Clynes M. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 28 (2007) 4302-4310
24. Ngai H.H., Sit W.H., Jiang P.P., Thongboonkerd V., and Wan J.M. Markedly increased urinary preprohaptoglobin and haptoglobin in passive heymann nephritis: a differential proteomics approach. J. Proteome Res. 6 (2007) 3313-3320
25. Yang Y.R., Liu S.L., Qin Z.Y., Liu F.J., Qin Y.J., Bai S.M., and Chen Z.Y. Comparative proteomics analysis of cerebrospinal fluid of patients with guillain-barre syndrome. Cell. Mol. Neurobiol. 28 (2008) 737-744
26. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., Kupchak P., Kireeva I., Ingratta L., and Jackowski G. Mining biomarkers in human sera using proteomic tools. Proteomics 4 (2004) 244-256
27. Mocchegiani E., Costarelli L., Giacconi R., Cipriano C., Muti E., and Malavolta M. Zinc-binding proteins (metallothionein and alpha-2 macroglobulin) and immunosenescence. Exp. Gerontol. 41 (2006) 1094-1107
28. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., and Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129 (2006) 3042-3050
29. Iacoviello L., Vischetti M., Zito F., and Benedetta Donati M. Genes encoding fibrinogen and cardiovascular risk. Hypertension 38 (2001) 1199-1203
30. Cheng A.J., Chen L.C., Chien K.Y., Chen Y.J., Chang J.T., Wang H.M., Liao C.T., and Chen I.H. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin. Chem. 51 (2005) 2236-2244
31. Wang P.W., Pan T.L., Lin C.H., Shen J.J., and Chen Y.R. Characterization of plasma protein profiles from patients with neurofibromatosis I. Clin. Chim. Acta 380 (2007) 139-144
32. Scott E.M., Ariens R.A., and Grant P.J. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1558-1566
33. Stibler H., Holzbach U., Tengborn L., and Kristiansson B. Complex functional and structural coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome type I. Blood Coagul. Fibrinol. 7 (1996) 118-126
34. Fiumara A., Barone R., Buttitta P., Musso R., Pavone L., Nigro F., and Jaeken J. Haemostatic studies in carbohydrate-deficient glycoprotein syndrome type I. Thromb. Haemost. 76 (1996) 502-504
35. Arnoux J.B., Boddaert N., Valayannopoulos V., Romano S., Bahi-Buisson N., Desguerre I., de Keyzer Y., Munnich A., Brunelle F., Seta N., Dautzenberg M.D., and de Lonlay P. Risk assessment of acute vascular events in congenital disorder of glycosylation type Ia. Mol. Genet. Metab. 93 (2008) 444-449
36. Pirard M., Matthijs G., Heykants L., Schollen E., Grunewald S., Jaeken J., and van Schaftingen E. Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2. FEBS Lett. 452 (1999) 319-322